T
Takashi Hamazaki
Researcher at Osaka City University
Publications - 86
Citations - 5768
Takashi Hamazaki is an academic researcher from Osaka City University. The author has contributed to research in topics: Stem cell & Embryonic stem cell. The author has an hindex of 27, co-authored 77 publications receiving 5275 citations. Previous affiliations of Takashi Hamazaki include University of Florida.
Papers
More filters
Journal ArticleDOI
Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion
Naohiro Terada,Takashi Hamazaki,Masahiro Oka,Masanori Hoki,Diana M. Mastalerz,Yuka Nakano,Edwin M. Meyer,Laurence Morel,Bryon E. Petersen,Edward W. Scott +9 more
TL;DR: It is demonstrated that mouse bone marrow cells can fuse spontaneously with embryonic stem cells in culture in vitro that contains interleukin-3, which, without detailed genetic analysis, might be interpreted as ‘dedifferentiation’ or transdifferentiation.
Journal ArticleDOI
Hepatic maturation in differentiating embryonic stem cells in vitro
Takashi Hamazaki,Yasuhiko Iiboshi,Masahiro Oka,Philip J. Papst,Amy Meacham,Leonard I. Zon,Naohiro Terada +6 more
TL;DR: The data indicate that the in vitro ES differentiation system has a potential to generate mature hepatocytes and has also been found useful in analyzing the role of growth factors and intracellular signaling molecules in hepatic development.
Journal ArticleDOI
Embryonic Stem Cells Proliferate and Differentiate when Seeded into Kidney Scaffolds
Edward A. Ross,Matthew J. Williams,Takashi Hamazaki,Naohiro Terada,William L. Clapp,Christopher A. Adin,Gary W. Ellison,Marda Jorgensen,Christopher D. Batich +8 more
TL;DR: It is suggested that the extracellular matrix can direct regeneration of the kidney, and studies using seeded scaffolds may help define differentiation pathways.
Journal ArticleDOI
A Heterogeneous Expression Pattern for Nanog in Embryonic Stem Cells
TL;DR: It is demonstrated that Nanog can directly repress Gata 6 expression through its binding to the proximal promoter region of the Gata6 gene and that overexpression of Nanog reduces heterogeneity during ES cell maintenance, suggesting methods to promote homogeneity during ES cells maintenance.
Journal ArticleDOI
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
Derralynn Hughes,Kathleen Nicholls,Suma P. Shankar,Gere Sunder-Plassmann,David M. Koeller,Khan Nedd,Gerard Vockley,Takashi Hamazaki,Robin H. Lachmann,Toya Ohashi,Iacopo Olivotto,Norio Sakai,Patrick Deegan,David Dimmock,François Eyskens,Dominique P. Germain,Ozlem Goker-Alpan,Eric Hachulla,Ana Jovanovic,Charles Marques Lourenço,Ichiei Narita,Mark Thomas,William R. Wilcox,Daniel G. Bichet,Raphael Schiffmann,Elizabeth Ludington,Christopher Viereck,John Kirk,Julie Yu,Franklin K. Johnson,Pol Boudes,Elfrida R. Benjamin,David J. Lockhart,Carrolee Barlow,Nina Skuban,Jeffrey P. Castelli,Jay A. Barth,Ulla Feldt-Rasmussen +37 more
TL;DR: Migalastat offers promise as a first-in-class oral monotherapy alternative treatment to intravenous ERT for patients with Fabry disease and amenable mutations.